Recruiting

Testing a New Intestinal Treatment for Type 2 Diabetes

Plain-English translation of NCT06267391 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Read our Type 2 Diabetes Mellitus research guide →

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a new procedure called ReCET therapy, which uses an endoscope (a thin tube with a camera) to deliver treatment inside your small intestine to help improve blood sugar control. The study will compare people who receive the real ReCET procedure with people who receive a sham procedure (where the device is inserted but no treatment is given) to see if this treatment is safe and effective for people with type 2 diabetes that isn't well controlled by their current medications.

Many people with type 2 diabetes struggle to control their blood sugar levels even while taking multiple medications. This trial exists to find out whether this new intestinal treatment could offer another option to help manage diabetes and reduce reliance on medications.

Do you qualify?

You likely qualify if…

you are between 22 and 70 years old
you have been diagnosed with type 2 diabetes for at least 6 months
your blood sugar control (HbA1C) is between 7.5 and 10.5%, measured by a lab
you are taking 2–4 non-insulin diabetes medications (or one GLP-1 medication) that haven't changed for at least 12 weeks
your weight has been stable for at least 12 weeks before enrollment
your body mass index (BMI) is between 27 and 40

You likely don't qualify if…

you have type 1 diabetes
you currently take insulin or have taken insulin for more than one month in the past 2 years
you have had previous stomach or bowel surgery that changed your digestive anatomy, such as gastric bypass or gastric banding
you have a history of severe stomach or intestinal problems, such as inflammatory bowel disease, strictures, or severe acid reflux
you are taking blood thinners like warfarin or certain newer anticoagulants that cannot be safely stopped

What participation looks like

You will be randomly assigned to either receive the ReCET procedure or a sham procedure (a procedure where the device is inserted but no treatment is given). The actual treatment involves an endoscopy, where a thin tube is passed through your mouth and into your small intestine to deliver the therapy. You'll have follow-up visits and monitoring for 6 months as the primary study period, with additional visits through 12 months total. After 12 months, people in the sham group will have the option to receive the real treatment.

AI-generated summary from trial data · Jun 26, 2026 · Not medical advice

Trial locations(45 sites)

United States

University of Alabama, Birmingham, Alabama

Central Alabama Research, Birmingham, Alabama

Velocity Clinical Research, Gardena, Gardena, California

Cedars-Sinai Medical Center, Los Angeles, California

UCLA, Los Angeles, California